loading page

Acute effect of add-on therapy with tofogliflozin, a sodium glucose co‐transporter 2 inhibitor, on 24-hour glucose profile and glycemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitors.
  • +6
  • Yoshimasa Aso,
  • Toshie Iijima,
  • Soichiro Hosonuma,
  • Hidetaka Kurai,
  • Hayato Kanitani,
  • Shintaro Sakurai,
  • Takuya Tomaru,
  • Teruo Jojima,
  • Isao Usui
Yoshimasa Aso
Dokkyo Medical University
Author Profile
Toshie Iijima
Dokkyo Medical University
Author Profile
Soichiro Hosonuma
Author Profile
Hidetaka Kurai
Author Profile
Hayato Kanitani
Author Profile
Shintaro Sakurai
Author Profile
Takuya Tomaru
Author Profile
Teruo Jojima
Author Profile

Abstract

Aim: To investigate acute effects of add-on therapy with the sodium glucose co‐transporter 2 inhibitor tofogliflozin to dipeptidyl peptidase (DPP)-4 inhibitors on 24-hour glucose profile and glycemic variability evaluated by continuous glucose monitoring (CGM) in patients with type 2 diabetes. Patients and methods: We studied 17 patients with type 2 diabetes who were hospitalized for glycemic control. CGM was performed for 7 consecutive days in the last week of hospitalization. Tofogliflozin 20 mg/day was started on day 4 after initiating CGM and was administered to 10 patients receiving DPP-4 inhibitors and 7 patients not receiving DPP-4 inhibitors. We compared several CGM parameters between day 2 to 3 (ie, before treatment with tofogliflozin) and day 5 to 6 (ie, after starting treatment with tofogliflozin). Results: After starting treatment with tofogliflozin, mean 24-hour glucose and postprandial glucose after each meal were significantly decreased in both groups of patients. Time in range (ie, at a glucose level of 70-180 mg/dL) was significantly increased in both groups. The standard deviation of 24-hour glucose and mean amplitude of glycemic excursions, 2 indexes of glycemic variability, were significantly decreased in patients receiving DPP-4 inhibitors but were unchanged in those not receiving these drugs. Conclusions: Add-on therapy with tofogliflozin to DPP-4 inhibitors acutely reduces 24-hour glucose levels and improves glycemic variability in patients with type 2 diabetes.

Peer review status:UNDER REVIEW

22 May 2021Submitted to International Journal of Clinical Practice
23 May 2021Assigned to Editor
23 May 2021Submission Checks Completed
02 Jun 2021Reviewer(s) Assigned